C 16G2

Drug Profile

C 16G2

Alternative Names: Antimicrobial peptide - C3J Therapeutics; C16G2

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator C3 Jian
  • Developer C3J Therapeutics
  • Class Antibacterials; Peptide antibiotics; Peptide fragments
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dental caries

Most Recent Events

  • 22 Dec 2016 C3 Jian plans a phase II trial for Dental caries (In adolescents, In adults, Prevention) in USA (Topical) (NCT03004365)
  • 19 Dec 2016 C3J Therapeutics plans a phase II trial for Dental caries in USA
  • 29 Nov 2016 C3 Jian is now called C3J Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top